AI Engines For more Details: Perplexity Kagi Labs You
Antimalarial Activity: Proguanil hydrochloride is effective in preventing and treating malaria caused by Plasmodium falciparum and other species of Plasmodium. It works by inhibiting the parasite's ability to metabolize and reproduce within the human host, thereby preventing the development and spread of the malaria infection.
Prophylaxis: Proguanil hydrochloride is commonly used for malaria prophylaxis in individuals traveling to regions where malaria is endemic. It is often used in combination with other antimalarial medications, such as chloroquine or atovaquone-proguanil, for enhanced efficacy and to prevent the development of drug resistance.
Treatment of Malaria: In addition to its prophylactic use, proguanil hydrochloride may also be used for the treatment of uncomplicated malaria, especially when combined with other antimalarial agents. It is typically used as part of a multidrug regimen to ensure effective clearance of the malaria parasite from the body.
Safe for Long-Term Use: Proguanil hydrochloride is considered safe for long-term use as a prophylactic medication for individuals residing in or traveling to malaria-endemic areas. It can be taken daily or weekly, depending on the specific regimen prescribed by a healthcare provider.
Side Effects: Common side effects associated with proguanil hydrochloride include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain. These side effects are usually mild and transient and may improve with continued use or dose adjustment.
Mouth Ulcers: Some individuals may experience the development of mouth ulcers (oral mucosal ulceration) while taking proguanil hydrochloride. This side effect typically resolves upon discontinuation of the medication but should be reported to a healthcare provider if severe or persistent.
Skin Reactions: Rarely, proguanil hydrochloride may cause skin reactions such as rash, itching, or photosensitivity (increased sensitivity to sunlight). Patients should be advised to use sun protection measures, such as wearing sunscreen and protective clothing, to minimize the risk of sunburn and skin irritation.
Hematologic Effects: Proguanil hydrochloride may rarely cause hematologic abnormalities, including leukopenia (reduced white blood cell count) and thrombocytopenia (reduced platelet count). Regular monitoring of blood cell counts may be recommended during prolonged therapy, especially in individuals with preexisting hematologic conditions.
Drug Interactions: Proguanil hydrochloride may interact with other medications, including anticoagulants (blood thinners) and certain anticonvulsants, potentially leading to increased or decreased blood levels of these drugs. Healthcare providers should be informed of all medications being taken by the patient to avoid potential drug interactions.
Pregnancy and Lactation: The safety of proguanil hydrochloride during pregnancy and breastfeeding has not been established conclusively. Pregnant or breastfeeding individuals should consult with their healthcare provider before using this medication to weigh the potential benefits against the risks to the fetus or infant.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
Acne | 0.3 | -0.3 | |
ADHD | 2.5 | 0.4 | 5.25 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
Allergic Rhinitis (Hay Fever) | 1.4 | 1.3 | 0.08 |
Allergies | 2.9 | 1.4 | 1.07 |
Allergy to milk products | 0.8 | 0.5 | 0.6 |
Alopecia (Hair Loss) | 0.5 | 0.5 | |
Alzheimer's disease | 1.9 | 3.7 | -0.95 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.8 | 1 |
Ankylosing spondylitis | 2.2 | 1 | 1.2 |
Anorexia Nervosa | 1 | -1 | |
Antiphospholipid syndrome (APS) | 0.6 | 0.4 | 0.5 |
Asthma | 1.2 | 1 | 0.2 |
Atherosclerosis | 0.7 | 0.8 | -0.14 |
Atrial fibrillation | 1.4 | 1.4 | 0 |
Autism | 6.3 | 5.9 | 0.07 |
Barrett esophagus cancer | 0.4 | 0.2 | 1 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 0.7 | 0.9 | -0.29 |
Brain Trauma | 0.6 | 0.4 | 0.5 |
Carcinoma | 2 | 1 | 1 |
Celiac Disease | 1.9 | 2.2 | -0.16 |
Cerebral Palsy | 1.2 | 0.4 | 2 |
Chronic Fatigue Syndrome | 3.5 | 2.6 | 0.35 |
Chronic Kidney Disease | 1.5 | 1.3 | 0.15 |
Chronic Lyme | 0.4 | -0.4 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 0.4 | 2.5 |
Chronic Urticaria (Hives) | 1.3 | 1 | 0.3 |
Coagulation / Micro clot triggering bacteria | 0.8 | 0.5 | 0.6 |
Colorectal Cancer | 2.2 | 0.9 | 1.44 |
Constipation | 1.2 | 0.3 | 3 |
Coronary artery disease | 1.4 | 0.3 | 3.67 |
COVID-19 | 5.7 | 6.1 | -0.07 |
Crohn's Disease | 4.8 | 2.5 | 0.92 |
cystic fibrosis | 0.6 | 0.7 | -0.17 |
deep vein thrombosis | 0.6 | 0.5 | 0.2 |
Depression | 4.9 | 5 | -0.02 |
Dermatomyositis | 0.2 | 0.3 | -0.5 |
Eczema | 1.3 | 1.3 | 0 |
Endometriosis | 1.4 | 0.3 | 3.67 |
Eosinophilic Esophagitis | 0.1 | 0.3 | -2 |
Epilepsy | 1.7 | 0.9 | 0.89 |
Fibromyalgia | 0.7 | 1.3 | -0.86 |
Functional constipation / chronic idiopathic constipation | 3.4 | 1.7 | 1 |
gallstone disease (gsd) | 0.9 | 0.7 | 0.29 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 0.2 | 6.5 |
Generalized anxiety disorder | 1.5 | 1.4 | 0.07 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.2 | -0.2 | |
Gout | 0.1 | -0.1 | |
Graves' disease | 0.7 | 0.8 | -0.14 |
Halitosis | 0.5 | 0.2 | 1.5 |
Hashimoto's thyroiditis | 1.1 | 0.8 | 0.38 |
Hidradenitis Suppurativa | 0.7 | 0.3 | 1.33 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.6 | 0.7 | 2.71 |
hypercholesterolemia (High Cholesterol) | 0.3 | 0.4 | -0.33 |
hyperglycemia | 0.2 | 0.9 | -3.5 |
Hyperlipidemia (High Blood Fats) | 0.8 | 0.3 | 1.67 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1.3 | 3.2 | -1.46 |
Hypothyroidism | 0.7 | -0.7 | |
Hypoxia | 0.3 | 0.3 | |
IgA nephropathy (IgAN) | 2.2 | -2.2 | |
Inflammatory Bowel Disease | 3.2 | 4.5 | -0.41 |
Insomnia | 0.3 | 0.4 | -0.33 |
Intelligence | 0.5 | 0.4 | 0.25 |
Intracranial aneurysms | 0.1 | 0.3 | -2 |
Irritable Bowel Syndrome | 2.1 | 2.6 | -0.24 |
Liver Cirrhosis | 2.5 | 2.2 | 0.14 |
Long COVID | 4.1 | 3.8 | 0.08 |
Low bone mineral density | 0.4 | -0.4 | |
Lung Cancer | 0.2 | 0.6 | -2 |
ME/CFS with IBS | 0.4 | 0.9 | -1.25 |
ME/CFS without IBS | 2.4 | 1 | 1.4 |
Menopause | 1.3 | 1.3 | |
Metabolic Syndrome | 5.1 | 5.6 | -0.1 |
Mood Disorders | 7.1 | 5.3 | 0.34 |
multiple chemical sensitivity [MCS] | 1 | 1 | |
Multiple Sclerosis | 4.2 | 2.6 | 0.62 |
Multiple system atrophy (MSA) | 1.6 | 0.3 | 4.33 |
Neuropathy (all types) | 0.4 | 0.2 | 1 |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.6 | 2.5 | -0.56 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 5 | 2 | 1.5 |
obsessive-compulsive disorder | 2.9 | 2.6 | 0.12 |
Osteoarthritis | 1.6 | 1.6 | |
Osteoporosis | 1.1 | 0.5 | 1.2 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 2.5 | 1.7 | 0.47 |
Polycystic ovary syndrome | 1.4 | 1 | 0.4 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
Premenstrual dysphoric disorder | 0.6 | 0.6 | |
primary biliary cholangitis | 0.2 | 0.5 | -1.5 |
Psoriasis | 2.9 | 1.3 | 1.23 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.6 | 2.2 | 1.09 |
Rosacea | 0.3 | 0.5 | -0.67 |
Schizophrenia | 4.4 | 0.9 | 3.89 |
scoliosis | 0.1 | 0.4 | -3 |
Sjögren syndrome | 1.6 | 1.4 | 0.14 |
Sleep Apnea | 0.4 | 0.8 | -1 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.7 | 0 |
Stress / posttraumatic stress disorder | 1.8 | 2.1 | -0.17 |
Systemic Lupus Erythematosus | 2.8 | 0.6 | 3.67 |
Tic Disorder | 0.9 | 1.2 | -0.33 |
Tourette syndrome | 0.2 | 0.1 | 1 |
Type 1 Diabetes | 2.4 | 1.9 | 0.26 |
Type 2 Diabetes | 5.7 | 4 | 0.43 |
Ulcerative colitis | 1.6 | 3.7 | -1.31 |
Unhealthy Ageing | 3.8 | 1.5 | 1.53 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.